Britain drug-cost watchdog says it will recommend Lilly obesity drug
Portfolio Pulse from
The UK's NICE will recommend Eli Lilly's obesity drug Mounjaro for use in the state health system, potentially reaching 220,000 people over three years.
December 05, 2024 | 12:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's obesity drug Mounjaro is recommended by the UK's NICE for use in the state health system, potentially reaching 220,000 people over three years.
The recommendation by NICE is a significant regulatory approval that could lead to increased sales and market penetration for Eli Lilly's Mounjaro in the UK. This is likely to positively impact Eli Lilly's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90